Bild: Studiensekretariat

Forschung im Leberzentrum: Klinische Studien

(Hinweis: Diese Seite gibt es nur in englischer Sprache.)

Sie befinden sich hier:

A multicenter, prospective, observational, cohort study of Tacni® (tacrolimus) or Ciqorin®/Vanquoral® (ciclosporin) and/or Myfenax® (mycophenolate mofetil), used in clinical practice for the prevention of acute rejection, in adult patients, after solid organ transplantation (kidney, heart, lung or liver)

An observational trial to detect an increase of compliance in liver transplant patients switched to a once-daily-preparation of tacrolimus.
Investigator initiated trial to reduce daily tacrolimus dose - the main risk factor for the development of acute toxicity and long term secondary organ damage and to improve adherence to the medication in stable liver transplant patients by switching to once-daily medication with Envarsus®.


A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response (STOP-NUC)


A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis


A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease


A Multicenter, Randomized, Double-Blind, Placebocontrolled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis


A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

CA209-459: A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (CheckMate 459)


A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicentre randomized trial (GRAFT)